OR WAIT 15 SECS
Lyophilization Services of New England acquired a sterile injectables manufacturing facility in León, Spain.
Lyophilization Services of New England (LSNE) announced the acquisition of a sterile injectables manufacturing facility located in León, Spain in a June 17, 2019 press release. The site, LSNE-León, will complement LSNE's existing full-service manufacturing capabilities and expand its reach into Europe.
In addition to adding pre-filled syringe, ophthalmic, and sterile bulk lyophilization capabilities, the new facility will also focus on pharmaceutical products that have complex requirements, such as emulsions, suspensions, liposomal formulations, and nanoparticle products. The facility includes four high-speed, automated aseptic fill lines and commercial-scale lyophilization for the manufacture of clinical and commercial drug products.
The León facility purchase is LSNE's second under the Permira funds' ownership. In April 2018, LSNE acquired a 37,000-ft2 cGMP aseptic fill/finish facility in Madison, Wisconsin.
LSNE-León is located northwest of Madrid in Spain's fastest growing pharmaceutical hub. The LSNE León facility has recently completed both FDA and Spanish Agency of Medicines and Medical Devices (AEMPS) inspections, and it is able to support large-scale commercial production in both the United States and the European Union.